000089729 001__ 89729
000089729 005__ 20210902121813.0
000089729 0247_ $$2doi$$a10.3390/jcm9040928
000089729 0248_ $$2sideral$$a118318
000089729 037__ $$aART-2020-118318
000089729 041__ $$aeng
000089729 100__ $$aRodriguez, L.A.G.
000089729 245__ $$aEffect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study
000089729 260__ $$c2020
000089729 5060_ $$aAccess copy available to the general public$$fUnrestricted
000089729 5203_ $$aEstimates of the effect of proton pump inhibitors (PPIs) on risks of upper and lower gastrointestinal bleeding (UGIB and LGIB) among low-dose aspirin users in routine clinical practice are variable (UGIB) or lacking (LGIB). We aimed to establish these risks in the same observational study population. Using UK primary care data, we followed 199, 049 new users of low-dose aspirin (75-300 mg/day) and matched non-users at start of follow-up to identify incident UGIB/LGIB cases. In nested case-control analyses, adjusted odds ratios (ORs) were calculated for concomitant PPI use vs. past (discontinued) PPI use among current low-dose aspirin users. For UGIB (n = 987), ORs (95% CIs) were 0.69 (0.54-0.88) for >1 month PPI use and 2.65 (1.62-4.3) for <= 1 month PPI use. Among the latter group, ORs (95% CIs) were 3.05 (1.75-5.33) for PPI initiation after start of aspirin therapy, and 1.66 (0.63-4.36) for PPI initiation on/before start of aspirin therapy. For LGIB (n = 1428), ORs (95% CIs) were 0.98 (0.81-1.17) for >1 month PPI use and 1.12 (0.73-1.71) for <= 1 month PPI use. Among low-dose aspirin users, maintaining PPI use (>1 month) was associated with a significantly reduced UGIB risk. Neither short nor long-term PPI use affected LGIB risk.
000089729 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000089729 590__ $$a4.241$$b2020
000089729 591__ $$aMEDICINE, GENERAL & INTERNAL$$b39 / 169 = 0.231$$c2020$$dQ1$$eT1
000089729 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000089729 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000089729 700__ $$aSoriano-Gabarro, M.
000089729 700__ $$aVora, P.
000089729 700__ $$aSoriano, L.C.
000089729 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000089729 773__ $$g9, 4 (2020), 928 [12 pp]$$pJ. clin.med.$$tJOURNAL OF CLINICAL MEDICINE$$x2077-0383
000089729 8564_ $$s264038$$uhttps://zaguan.unizar.es/record/89729/files/texto_completo.pdf$$yVersión publicada
000089729 8564_ $$s461196$$uhttps://zaguan.unizar.es/record/89729/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000089729 909CO $$ooai:zaguan.unizar.es:89729$$particulos$$pdriver
000089729 951__ $$a2021-09-02-10:02:45
000089729 980__ $$aARTICLE